论文部分内容阅读
目的:研究晚期胃癌患者血管内皮生长因子(VEGF)和肿瘤坏死因子(TNF-a)水平变化在治疗前后中的意义。方法:将60例胃癌患者随机分为两组各30例,应用酶联免疫吸附法(ELISA)测定60例胃癌患者治疗前和治疗后一个月血清VEGF和TNF-a的含量变化,结合临床病理学资料进行分析;治疗组为沙利度胺联合治疗的30例晚期胃癌患者;对照组为单纯化疗的30例晚期胃癌患者。结果:治疗组治疗有效的患者治疗后血清VEGF和TNF-a水平明显下降,与治疗前的水平有显著性差异(P<0.05);对照组治疗前后血清VEGF和TNF-a水平下降不明显,无显著性差异(P>0.05)。结论:晚期胃癌患者通过沙利度胺联合治疗后血清VEGF、TNF-a的水平明显下降,所以我们通过血清VEGF、TNF-a的含量变化可作为胃癌患者疗效预测的参考指标。
Objective: To study the significance of changes of vascular endothelial growth factor (VEGF) and tumor necrosis factor (TNF-a) levels in patients with advanced gastric cancer before and after treatment. Methods: Sixty patients with gastric cancer were randomly divided into two groups: 30 cases were treated with ELISA. Serum VEGF and TNF-a levels were measured in 60 patients with gastric cancer before and after treatment, combined with clinical disease. The data were analyzed; 30 patients with advanced gastric cancer were treated with thalidomide in the treatment group, and 30 patients with advanced gastric cancer were treated with chemotherapy alone in the control group. Results: Serum levels of VEGF and TNF-a in treatment group were significantly lower after treatment than those before treatment (P<0.05). Serum VEGF and TNF-a levels were not significantly decreased in the control group before and after treatment. No significant difference (P>0.05). Conclusion: The serum levels of VEGF and TNF-a in patients with advanced gastric cancer after treatment with thalidomide decreased significantly. Therefore, we can use serum VEGF and TNF-a levels as reference indicators for predicting the efficacy of gastric cancer patients.